SummaryAmong breast cancers, triple-negative breast cancer (TNBC) is the most poorly understood and is refractory to current targeted therapies. Using a genetic screen, we identify the PTPN12 tyrosine phosphatase as a tumor suppressor in TNBC. PTPN12 potently suppresses mammary epithelial cell proliferation and transformation. PTPN12 is frequently compromised in human TNBCs, and we identify an upstream tumor-suppressor network that posttranscriptionally controls PTPN12. PTPN12 suppresses transformation by interacting with and inhibiting multiple oncogenic tyrosine kinases, including HER2 and EGFR. The tumorigenic and metastatic potential of PTPN12-deficient TNBC cells is severely impaired upon restoration of PTPN12 function or combined inhi...
Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor ...
Disruption of the balanced modulation of reversible tyrosine phosphorylation has been implicated in ...
Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise diseas...
SummaryAmong breast cancers, triple-negative breast cancer (TNBC) is the most poorly understood and ...
“Triple-negative” breast cancers are aggressive malignancies that respond poorly to treatments. Now ...
“Triple-negative” breast cancers are aggressive malignancies that respond poorly to treatments. Now ...
Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a recently identified tumor suppressor...
Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a recently identified tumor suppressor...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
PurposeThe protein tyrosine phosphatase PTPN2 dephosphorylates several tyrosine kinases in cancer-re...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor ...
Disruption of the balanced modulation of reversible tyrosine phosphorylation has been implicated in ...
Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise diseas...
SummaryAmong breast cancers, triple-negative breast cancer (TNBC) is the most poorly understood and ...
“Triple-negative” breast cancers are aggressive malignancies that respond poorly to treatments. Now ...
“Triple-negative” breast cancers are aggressive malignancies that respond poorly to treatments. Now ...
Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a recently identified tumor suppressor...
Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a recently identified tumor suppressor...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
International audienceClinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an a...
PurposeThe protein tyrosine phosphatase PTPN2 dephosphorylates several tyrosine kinases in cancer-re...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
International audienceThe protein tyrosine phosphatase PTPL1/PTPN13, the activity of which is decrea...
Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor ...
Disruption of the balanced modulation of reversible tyrosine phosphorylation has been implicated in ...
Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise diseas...